EE95 Cost-Effectiveness Analysis of Pemigatinib for the Treatment of Adult Patients with Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement That Have Progressed After Systemic Therapy in Greece
Abstract
Authors
C. Tzanetakos M. Psarra M. Batsi K. Patterson Z. Vostitsanou G. Gourzoulidis